UK POM-To-P Switches At End-June
At the end of this month, a number of prescription-Only to Pharmacy switches will be implemented by the UK Medicines Control Agency.
Pfizer's Diflucan (fluconazole) will be switched to P status for the oral treatment of vaginal candidiasis in women aged between 16 and 60, while Janssen's Nizoral (ketoconazole) will be switched for the prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp. UCB's Atarax and Userax (hydroxyzine hydrochloride) will be switched for the management of pruritis associated with acute or chronic urticaria, atopic dermatitis or contract dermatitis (not for children aged under six), and Pfizer's Combantrin (pyrantel embonate) becomes available as a P product for the treatment of emerobiasis (not for children aged under two).
In addition, the maximum daily dose for pseudoephedrine hydrochloride as a P product is to be increased from 180mg to 240mg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze